ITGA5 (Integrin Alpha-5 / CD49e) Drug Discovery Landscape & Assay Solutions
- By admin
- 31 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Fibrosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ITGA5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ITGA5 & ITGB1 Heterodimer Protein HEK293 expressed, native glycosylation, sequence verified. High purity (>95%), endotoxin controlled. |
View ITGA5 Products |
| Gene Delivery | ITGA5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation (Flow Cytometry & Adhesion Assays). |
View ITGA5 Products |
| Benchmark Ab | Anti-ITGA5 Recombinant Antibody Volociximab sequence-derived biosimilar for positive control and benchmark assays. |
View ITGA5 Products |
| Validator | ITGA5 siRNA Set Target-specific knockdown verification in functional cell-based assays. |
View ITGA5 Products |
| Related Target A | ITGB1 (Integrin Beta-1) Required heterodimerization partner for functional fibronectin receptor assembly. |
View ITGB1 Products |
| Related Target B | FN1 (Fibronectin) Primary endogenous ligand used to evaluate blocking efficacy of anti-ITGA5 therapeutics. |
View FN1 Products |
| Related Target C | ITGAV (Integrin Alpha-V) Homologous alpha integrin subunit used for selectivity and off-target counter-screening. |
View ITGAV Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Heterodimerization | Co-expressed ITGA5/ITGB1 soluble heterodimer proteins with native folding. |
| Integrin Subfamily Cross-Reactivity | Selectivity panels including ITGAV and other integrin alpha subunits for counter-screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Volociximab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
Live ITGA5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ITGA5 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to antibody-drug conjugates (ADCs) and bispecific antibodies targeting the tumor microenvironment (TME). As first-generation therapies reach the clinic, the next wave of R&D is targeting stromal depletion, overcoming immunotherapy resistance, and treating fibrotic disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Eisai, Biotech Startups | Solid Tumors (Ovarian, NSCLC) | Internalization Assay (Need high-purity ECD-Fc & stable cell lines) |
| Bispecific / Multi-specific | AstraZeneca, Roche | Tumor Microenvironment / Fibrosis | Heterodimer Validation (Need cross-reactive antigens & ligand blocking assays) |
| Small Molecule / Peptide | Clinical-stage Biotechs | NASH / Liver Fibrosis, Wet AMD | High-throughput Screening (Need stable ITGA5/ITGB1 expressing cell lines) |